SCG Cell Therapy Posts Solid Results for HBV T Cell Therapy

Singapore’s SCG Cell Therapy Pte announced positive data from a first-in-class autologous hepatitis B virus-specific T-cell receptor-engineered T Cell therapy. In six patients with advanced HBV-HCC, SCG101 produced an objective response rate of 33%. SCG develops novel immunotherapies for infections and their associated cancers, targeting the most common cancer-causing infections: helicobacter pylori, HPV, HBV and EBV. It also develops TCR-based cellular immunotherapy products against infection- associated cancers. The trial data was included in the recent Best of EASL Congress Wrap-Up summary at the European Association for the Study of the Liver Congress in Milan, Italy.  More details....

Share this with colleagues: